ClearWay Rx Readmission Registry

Completed

Conditions studied: Acute Myocardial Infarction

In brief

The purpose of this registry is to determine if delivery of weight adjusted, in a large dose with either Abcixmab or Eptifibitide through the ClearWay™ RX, in patients admitted for primary coronary intervention lowers readmission rate. This is done in comparison to the historical control of the Medicare/Medicaid readmission database. The registry will record the use of the product during the index procedure, and determine whether or not the patient was readmitted within 30 days, related to the index procedure.

Key facts

Study ID

NCT01673893

Run by

Cardiovascular Institute of the South Clinical Research Corporation

People needed

59

Starts

2011-09-01

Expected to finish

2014-04-01

Last updated by the study team

2018-11-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Acute Coronary Syndrome (ST elevation myocardial infarction or Non ST elevation myocardial infarction) patients requiring the use of the ClearWay™ Rx local therapeutic infusion catheter for intracoronary delivery of GP IIb/IIIa inhibitor.

You may not qualify if…

• Patients not meeting the above inclusion criterion

Where it is running

• Cardiovascular Institute of the South Clinical Research Corporation — Lafayette, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.